Document is current
Any future updates will be listed below
-
Authors
Lomakin, Nikita V. https://orcid.org/0000-0001-8830-7231
Bakirov, Bulat A. https://orcid.org/0000-0002-3297-1608
Protsenko, Denis N. https://orcid.org/0000-0002-5166-3280
Mazurov, Vadim I. https://orcid.org/0000-0002-0797-2051
Musaev, Gaziyavdibir H. https://orcid.org/0000-0002-6550-7975
Moiseeva, Olga M. https://orcid.org/0000-0002-7817-3847
Pasechnik, Elena S. https://orcid.org/0000-0001-6217-2818
Popov, Vladimir V. https://orcid.org/0000-0002-1570-2748
Smolyarchuk, Elena A. https://orcid.org/0000-0002-2615-7167
Gordeev, Ivan G. https://orcid.org/0000-0002-3233-4369
Gilyarov, Mikhail Yu https://orcid.org/0000-0002-2870-3301
Fomina, Darya S. https://orcid.org/0000-0002-5083-6637
Seleznev, Anton I. https://orcid.org/0000-0001-9582-7921
Linkova, Yulia N. https://orcid.org/0000-0002-5463-1022
Dokukina, Ekaterina A. https://orcid.org/0000-0002-6759-673X
Eremeeva, Anna V. https://orcid.org/0000-0001-5196-6911
Pukhtinskaia, Polina S. https://orcid.org/0000-0001-9790-8207
Morozova, Maria A. https://orcid.org/0000-0001-7755-7526
Zinkina-Orikhan, Arina V. https://orcid.org/0000-0002-8499-2232
Lutckii, Anton A. https://orcid.org/0000-0003-2884-1568
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04397562 at ClinicalTrials.govDocuments that mention this clinical trial
POS1214 THE DYNAMICS OF INFLAMMATORY MARKERS IN COVID-19 PATIENTS TREATED WITH LEVILIMAB
https://doi.org/10.1136/annrheumdis-2021-eular.2509
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study
https://doi.org/10.1007/s00011-021-01507-5
POS0624 EFFICACY AND SAFETY OF LEVILIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS: PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2443
POS0649 EFFICACY AND SAFETY OF LEVILIMAB IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULTS OF PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.2680
-
Funding
Funding for this research was provided by:
JSC BIOCAD (BCD-089-4/CORONA)
- License Information
-
More Information
Article History
Received: 11 July 2021
Revised: 14 September 2021
Accepted: 16 September 2021
First Online: 29 September 2021
Declarations
:
: The research leading to these results received funding from BIOCAD under Grant Agreement No BCD-089-4/CORONA. Authors Nikita V. Lomakin, Bulat A. Bakirov, Denis N. Protsenko, Vadim I. Mazurov, Gaziyavdibir H. Musaev, Olga M. Moiseeva, Elena S. Pasechnik, Vladimir V. Popov, Elena A. Smolyarchuk, Ivan G. Gordeev, Darya S. Fomina have no conflicts of interest to declare that are relevant to the content of this article. Author Mikhail Yu. Gilyarov received a speaking fee from Boehringer Ingelheim, Bayer, Pfizer и Servier. Authors Anton I. Seleznev, Yulia N. Linkova, Ekaterina A. Dokukina, Polina S. Pukhtinskaia, Anna V. Eremeeva, Maria A. Morozova, Arina V. Zinkina-Orikhan and Anton A. Lutckii, are JSC BIOCAD employees.
: This study was performed in line with the principles of the Declaration of Helsinki of 1964, and its later amendments and was approved by the Central Regulatory Authorities of the Russian Federation (Authorization by the Ministry of Healthcare of the Russian Federation No. 176 of April 22, 2020; Extract from minutes of Ethics Council of Ministry of Health of The Russian Federation No.216, dated 21th of April, 2020) and Ethical Review Boards of each of the participating sites.
: Informed consent was obtained from all individual participants included in the study.
: There is no identifiable information in the manuscript. Patients signed informed consent which included information about publishing the analyzed data.
